nach oben

Endocrine

Erschienen in:

24.08.2017 | Original Article

The roles of microRNA-34b-5p in angiogenesis of thyroid carcinoma

verfasst von: Hamidreza Maroof, Farhadul Islam, Armin Ariana, Vinod Gopalan, Alfred K. Lam

Erschienen in: Endocrine | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aims to determine the expression of miR-34b-5p in thyroid carcinomas and to investigate the role of miR34b-5p in the modulation of proteins involved in angiogenesis of thyroid carcinoma cells.

Methods

The expressions of miR-34b-5p levels in five cell lines and 65 tissue samples from thyroid carcinomas were examined by real-time polymerase chain reaction. An exogenous miR-34b-5p (mimic) transiently overexpress miR-34b-5p in theses thyroid carcinoma cells. The effects of miR-34b-5p overexpression on the proteins involved in angiogenesis and cell cycle regulations (VEGF-A, Bcl-2 and Notch1) were investigated by Western blot, immunofluorescence, enzyme-linked immunosorbent assay followed by cell cycle analysis and apoptosis assays.

Results

miR-34b-5p is markedly downregulated in all thyroid carcinoma cell lines and tissues samples when compared with non-neoplastic immortalised thyroid cell line and non-neoplastic thyroid tissues, respectively. The expression levels of miR-34b were significantly associated with T-stages of thyroid carcinomas (p = 0.042). Downregulation of VEGF-A, Bcl-2 and Notch1 proteins in thyroid carcinoma cells were noted in cells that transiently transfected with miR-34b-5p mimic. In addition, enzyme-linked immunosorbent assay confirmed the decreased expression of VEGF in thyroid carcinoma cells after transfection with miR-34b-5p mimic. Furthermore, miR-34b-5p mimic transfection induces significant accumulation of cells in G0-G1 of the cell cycle by blocking of their entry into the S transitional phase as well as increasing the total apoptosis.

Conclusions

miR-34b-5p functions as a potent regulator of angiogenesis, apoptosis and cell proliferation via modulation of VEGF-A, Bcl-2 and Notch1 proteins. It could be a target for developing treatment strategies of thyroid carcinoma with aggressive clinical behaviour.

Nur mit Berechtigung zugänglich

A.K. Lam, C.Y. Lo, K.S. Lam, Papillary carcinoma of thyroid: a 30-yr clinicopathological review of the histological variants. Endocr. Pathol. 16, 323–330 (2005)CrossRefPubMed

K.Y. Lam, C.Y. Lo, K.W. Chan, K.Y. Wan, Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann. Surg. 231, 329–338 (2000)CrossRefPubMedPubMedCentral

J. Weekes, Y.H. Ho, S. Sebesan, K. Ong, A.K. Lam, Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression. Int. J. Colorectal. Dis. 25, 907 (2010)CrossRefPubMed

W.W. Xu, B. Li, A.K. Lam, S.W. Tsao, S.Y. Law, K.W. Chan, Q.J. Yuan, A.L. Cheung, Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy. Oncotarget 6, 1790–1805 (2015)CrossRefPubMed

X.M. Yu, C.Y. Lo, W.F. Chan, K.Y. Lam, P. Leung, J.M. Luk, Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin. Cancer Res. 11, 8063–8069 (2005)CrossRefPubMed

X.M. Yu, C.Y. Lo, A.K. Lam, B.H. Lang, P. Leung, J.M. Luk, The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery 144, 934–940 (2008)CrossRefPubMed

X.M. Yu, C.Y. Lo, A.K. Lam, P. Leung, J.M. Luk, Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann. Surg. 247, 483–489 (2008)CrossRefPubMed

A. Caporali, C. Emanueli, MicroRNA regulation in angiogenesis. Vascul. Pharmacol. 55, 79–86 (2011)CrossRefPubMed

J. Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27–30 (1995)CrossRefPubMed

10.

M. Meyer, M. Clauss, A. Lepple-Wienhues, J. Waltenberger, H.G. Augustin, M. Ziche, C. Lanz, M. Buttner, C. Dehio, A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18, 363–374 (1999)CrossRefPubMedPubMedCentral

11.

I. Stalmans, D. Lambrechts, F. De Smet, S. Jansen, J. Wang, S. Maity, P. Kneer, M. von der Ohe, A. Swillen, C. Maes, M. Gewillig, D.G. Molin, P. Hellings, T. Boetel, M. Haardt, V. Compernolle, M. Dewerchin, S. Plaisance, R. Vlietinck, B. Emanuel, A.C. Gittenberger-de Groot, P. Scambler, B. Morrow, D.A. Driscol, L. Moons, C.V. Esguerra, G. Carmeliet, A. Behn-Krappa, K. Devriendt, D. Collen, S.J. Conway, P. Carmeliet, VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat. Med. 9, 173–182 (2003)CrossRefPubMed

12.

A. Salajegheh, H. Vosgha, M.A. Rahman, M. Amin, R.A. Smith, A.K. Lam, Interactive role of miR-126 on VEGF-A and progression of papillary and undifferentiated thyroid carcinoma. Hum. Pathol. 51, 75–85 (2016)CrossRefPubMed

13.

D.G. Duda, T.T. Batchelor, C.G. Willett, R.K. Jain, VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol. Med. 13, 223–230 (2007)CrossRefPubMedPubMedCentral

14.

O. Casanovas, D.J. Hicklin, G. Bergers, D. Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299–309 (2005)CrossRefPubMed

15.

P.T. Finger, K.J. Chin, E.A. Semenova, Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study. Eur. J. Ophthalmol. 26, 60–66 (2016)CrossRefPubMed

16.

P.T. Finger, S.K. Mukkamala, Intravitreal anti-VEGF bevacizumab (Avastin) for external beam related radiation retinopathy. Eur. J. Ophthalmol. 21, 446–451 (2011)CrossRefPubMed

17.

L.C. Harshman, W. Xie, G.A. Bjarnason, J.J. Knox, M. MacKenzie, L. Wood, S. Srinivas, U.N. Vaishampayan, M.H. Tan, S.Y. Rha, F. Donskov, N. Agarwal, C. Kollmannsberger, S. North, B.I. Rini, D.Y. Heng, T.K. Choueiri, Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol. 13, 927–935 (2012)CrossRefPubMed

18.

G. Lupo, N. Caporarello, M. Olivieri, M. Cristaldi, C. Motta, V. Bramanti, R. Avola, M. Salmeri, F. Nicoletti, C.D. Anfuso, Anti-angiogenic therapy in cancer: Downsides and new pivots for precision medicine. Front. Pharmacol. 7, 519 (2016)PubMed

19.

H. Maroof, A. Salajegheh, R.A. Smith, A.K. Lam, MicroRNA-34 family, mechanisms of action in cancer: a review. Curr. Cancer Drug Targets 14, 737–751 (2014)CrossRef

20.

H. Maroof, A. Salajegheh, R.A. Smith, A.K. Lam, Role of microRNA-34 family in cancer with particular reference to cancer angiogenesis. Exp. Mol. Pathol. 97, 298–304 (2014)CrossRefPubMed

21.

L. Yip, L. Kelly, Y. Shuai, M.J. Armstrong, Y.E. Nikiforov, S.E. Carty, M.N. Nikiforova, MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann. Surg. Oncol. 18, 2035–2041 (2011)CrossRefPubMed

22.

B.C. Bernardo, X.M. Gao, C.E. Winbanks, E.J. Boey, Y.K. Tham, H. Kiriazis, P. Gregorevic, S. Obad, S. Kauppinens, X.J. Du, R.C. Lin, J.R. McMullen, Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc. Natl. Acad. Sci. USA 109, 17615–17620 (2012)CrossRefPubMedPubMedCentral

23.

Q. Ji, X. Hao, Y. Meng, M. Zhang, J. DeSano, D. Fan, L. Xu, Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 8, 266 (2008)CrossRefPubMedPubMedCentral

24.

X.P. Li, W. Jing, J.J. Sun, Z.Y. Liu, J.T. Zhang, W. Sun, W. Zhu, Y.Z. Fan, A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 “multi-points priming” mechanisms in vitro and in vivo. BMC Cancer 15, 527 (2015)CrossRefPubMedPubMedCentral

25.

L. Liu, L. Liu, J. Shi, M. Tan, J. Xiong, X. Li, Q. Hu, Z. Yi, D. Mao, MicroRNA-34b mediates hippocampal astrocyte apoptosis in a rat model of recurrent seizures. BMC Neurosci 17, 56 (2016)CrossRefPubMedPubMedCentral

26.

W. Ye, Q. Lv, C.K. Wong, S. Hu, C. Fu, Z. Hua, G. Cai, G. Li, B.B. Yang, Y. Zhang, The effect of central loops in miRNA:MRE duplexes on the efficiency of miRNA-mediated gene regulation. PLoS One 3, e1719 (2008)CrossRefPubMedPubMedCentral

27.

F. Islam, V. Gopalan, S. Law, J.C. Tang, K.W. Chan, A.K. Lam, MiR-498 in esophageal squamous cell carcinoma: clinicopathological impacts and functional interactions. Hum. Pathol. 62, 141–151 (2017)CrossRefPubMed

28.

V. Gopalan, F. Islam, S. Pillai, J.C. Tang, D.K. Tong, S. Law, K.W. Chan, A.K. Lam, Overexpression of microRNA-1288 in oesophageal squamous cell carcinoma. Exp. Cell Res. 348, 146–154 (2016)CrossRefPubMed

29.

F. Islam, V. Gopalan, J. Vider, R. Wahab, F. Ebrahimi, C.T. Lu, K. Kasem, A.K.Y. Lam, MicroRNA-186-5p overexpression modulates colon cancer growth by repressing the expression of the FAM134B tumour inhibitor. Exp. Cell Res. 357, 260–270 (2017)CrossRefPubMed

30.

F. Islam, V. Gopalan, R. Wahab, R.A. Smith, B. Qiao, A.K. Lam, Stage dependent expression and tumor suppressive function of FAM134B (JK1) in colon cancer. Mol. Carcinog. 56, 238–249 (2017)CrossRefPubMed

31.

Y. Huang, D. Liao, L. Pan, R. Ye, X. Li, S. Wang, C. Ye, L. Chen, Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. Eur. J. Endocrinol. 168, 675–681 (2013)CrossRefPubMed

32.

X. Li, Z. Wang, The role of noncoding RNA in thyroid cancer. Gland Surg. 1, 146–150 (2012)PubMedPubMedCentral

33.

A. Salajegheh, S. Pakneshan, A. Rahman, E. Dolan-Evans, S. Zhang, E. Kwong, V. Gopalan, C.Y. Lo, R.A. Smith, A.K.Y. Lam, Co-regulatory potential of vascular endothelial growth factor–A and vascular endothelial growth factor–C in thyroid carcinoma. Hum. Pathol. 44, 2204–2212 (2013)CrossRefPubMed

34.

J. Xiao, Y. Li, W. Zhang, Y. Jiang, B. Du, Y. Tan, miR-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22. Onco Targets Ther. 9, 1525–1534 (2016)CrossRefPubMedPubMedCentral

35.

Y. Xie, P. Zong, W. Wang, D. Liu, B. Li, Y. Wang, J. Hu, Y. Ren, Y. Qi, X. Cu, Y. Chen, C. Liy, F. Li, Hypermethylation of potential tumor suppressor miR-34b/c is correlated with late clinical stage in patients with soft tissue sarcomas. Exp. Mol. Pathol. 98, 446–454 (2015)CrossRefPubMed

36.

D.C. Corney, A. Flesken-Nikitin, A.K. Godwin, W. Wang, A.Y. Nikitin, MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 67, 8433–8438 (2007)CrossRefPubMed

37.

L.G. Wang, Y. Ni, B.H. Su, X.R. Mu, H.C. Shen, J.J. Du, MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met. Int. J. Oncol. 42, 957–962 (2013)CrossRefPubMed

38.

K.Y. Wong, R.L. Yim, C.C. So, D.Y. Jin, R. Liang, C.S. Chim, Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood 118, 5901–5904 (2011)CrossRefPubMed

39.

T. Kangsamaksin, I.W. Tattersall, J. Kitajewski, Notch functions in developmental and tumour angiogenesis by diverse mechanisms. Biochem. Soc. Trans. 42, 1563–1568 (2014)CrossRefPubMed

40.

C. Geers, I.M. Colin, A.C. Gerard, Delta-like 4/Notch pathway is differentially regulated in benign and malignant thyroid tissues. Thyroid 21, 1323–1330 (2011)CrossRefPubMed

41.

M. Kunnimalaiyaan, H. Chen, Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist 12, 535–542 (2007)CrossRefPubMed

42.

A.S. Yamashita, M.V. Geraldo, C.S. Fuziwara, M.A. Kulcsar, C.U. Friguglietti, R.B. da Costa, G.S. Baia, E.T. Kimura, Notch pathway is activated by MAPK signaling and influences papillary thyroid cancer proliferation. Transl. Oncol. 6, 197–205 (2013)CrossRefPubMedPubMedCentral

43.

A. Fernandez, T. Udagawa, C. Schwesinger, W. Beecken, E. Achilles-Gerte, T. McDonnell, R. D’Amato, Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J. Natl. Cancer Inst. 93, 208–213 (2001)CrossRefPubMed

44.

T.J. McDonnell, P. Troncoso, S.M. Brisbay, C. Logothetis, L.W. Chung, J.T. Hsieh, S.M. Tu, M.L. Campbell, Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52, 6940–6944 (1992)PubMed

45.

A. Takaoka, M. Adachi, H. Okuda, S. Sato, A. Yawata, Y. Hinoda, S. Takayama, K. Imai, Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene 14, 2971–2977 (1997)CrossRefPubMed

46.

K. Kuramoto, T. Uesaka, A. Kimura, M. Kobayashi, H. Watanabe, O. Katoh, ZK7, a novel zinc finger gene, is induced by vascular endothelial growth factor and inhibits apoptotic death in hematopoietic cells. Cancer Res. 60, 425–430 (2000)PubMed

47.

A. Biroccio, D. Del Bufalo, M. Fanciulli, T. Bruno, G. Zupi, A. Floridi, bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells. Int. J. Cancer 82, 125–130 (1999)CrossRefPubMed

48.

A. Iervolino, D. Trisciuoglio, D. Ribatti, A. Candiloro, A. Biroccio, G. Zupi, D. Del Bufalo, Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J. 16, 1453–1455 (2002)PubMed

49.

Q. Ji, X. Hao, M. Zhang, W. Tang, M. Yang, L. Li, D. Xiang, J.T. Desano, G.T. Bommer, D. Fan, E.R. Fearon, T.S. Lawrence, L. Xu, MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4, e6816 (2009)CrossRefPubMedPubMedCentral

50.

Z. Hagman, O. Larne, A. Edsjo, A. Bjartell, R.A. Ehrnstrom, D. Ulmert, H. Lilja, Y. Ceder, miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int. J. Cancer 127, 2768–2776 (2010)CrossRefPubMed

51.

C. Welch, Y. Chen, R.L. Stallings, MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26, 5017–5022 (2007)CrossRefPubMed

52.

Y. Zhou, R.H. Zhao, K.F. Tseng, K.P. Li, Z.G. Lu, Y. Liu, K. Han, Z.H. Gan, S.C. Lin, H.Y. Hu, D.L. Min, Sirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expression. Acta Pharmacol. Sin. 37, 519–529 (2016)CrossRefPubMedPubMedCentral

53.

D. Betel, A. Koppal, P. Agius, C. Sander, C. Leslie, Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11, R90 (2010)CrossRefPubMedPubMedCentral

Titel: The roles of microRNA-34b-5p in angiogenesis of thyroid carcinoma
verfasst von: Hamidreza Maroof
Farhadul Islam
Armin Ariana
Vinod Gopalan
Alfred K. Lam
Publikationsdatum: 24.08.2017
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-017-1393-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The roles of microRNA-34b-5p in angiogenesis of thyroid carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Increase in the circulating endocannabinoid 2-arachidonoylglycerol is associated with gabapentin use in septic ICU patients

Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009–2015

Association between vitamin D and sperm parameters: Clinical evidence

Acid–base safety during the course of a very low-calorie-ketogenic diet

Growth hormone deficiency and hypopituitarism in adults after complicated mild traumatic brain injury

JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin